Adam Wojciech Lukojc

CSAM-P operates as part of CSGN, which aims to create value for shareholders by taking advantage of their global integrated network. CSGN actively manages funds across asset classes, geographic regions, sectors and strategies. Their investment philosophy is growth-oriented and research-driven, and combines a top-down approach for asset allocation with a bottom-up approach for stock selection. The firm's fixed-income portfolios cover major markets including emerging markets. They base fixed-income investments on the analysis of macroeconomic trends, currency fluctuation, credit risk, and company valuation. They also offers liquidity funds, as well as balanced products at the domestic, international and global level.

Allianz Polska is an active, growth and value-oriented investment manager which pursues a long-term investment philosophy with primary research as the basis for investment decisions. The firm seeks to invest in Polish equity, government bonds and corporate bonds debt, seeking small- to mid-cap companies with solid growth prospects. The selection process is bottom-up, sector-based and supplemented by a top-down allocation.

Skarbiec is a long-term, growth and value-oriented manager which follows a variety of investment strategies to manage their portfolios, including fixed-income, growth, balanced, -asset allocation and aggressive strategies. The firm invests across sectors and market caps in Polish equity, government bonds, real estate, fund of funds and money market instruments. Their research analysts perform in-house research, including company visits, which portfolio managers use to construct diversified portfolios. Portfolio managers make investment decisions for their funds, each of which follows a specific benchmark.

Functions as a College/University

Functions as a College/University

IPOPEMA Asset Management manages diverse investment products including open-end and close-end funds.

Sells gold and silver bullion and diamonds

Operates as a a biopharmaceutical company which develops protein degradation drugs for cancer and autoimmune diseases